Introduction
The anesthetic propofol was first approved in Europe in 1986 for induction and maintenance of anesthesia in adults and children over 3 years of age, and for sedation of adult patients in the ICU. Since its introduction, the drug has gained widespread popularity because of rapid onset and short recovery times even after prolonged administration [1] . The latter is especially important in patients with traumatic brain injury (TBI) in which the possibility of timely neurological assessment may be highly desirable [2] . Furthermore, propofol reduces cerebral metabolic demand, facilitates control of intracranial hypertension, and possibly has added neuroprotective and anticonvulsive properties [3] .
Propofol (2,6-diisopropylphenol in 10% soybean oil) is an alkylphenol derivative structurally unrelated to other anesthetic agents. It undergoes hepatic metabolism by conjugation to propofol glucuronide, quinol glucuronide and 4-quinol sulfate. These water-soluble compounds are excreted by the kidneys.
Although propofol has been administered for general anesthesia safely millions of times over the past two decades [4, 5] , an increasing number of reports have appeared since 1992 describing potentially fatal complications after prolonged infusions of the drug [6] . These adverse effects, which were first described in children [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and later in adults [3, 9, 19, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] , included rapidly progressive myocardial failure, bradycardia, lactic acidosis, rhabdomyolysis, hyperkalemia, lipemia, acute renal failure, and eventually death. Their concurrence has since been termed the propofol infusion syndrome (PRIS). Table 1 shows the characteristics of the 22 cases of the PRIS in patients with TBI that have been reported in the literature to date. Table 2 summarizes the most important clinical features, divided by their time of occurrence. As a first manifestation of the syndrome, laboratory testing will often reveal otherwise unexplained lactic acidosis [44] [45] [46] [47] , although Cravens et al. [44] demonstrated a 24% incidence of mild metabolic acidosis in patients on propofol undergoing radiofrequency ablation for atrial flutter or fibrillation who suffered no further symptoms of the PRIS. Fudickar et al. [48 ] recently reported a case of the PRIS without lactic acidosis. Lipemia has also been reported in most cases of the PRIS [6, 49] , but a rise in serum triglycerides may occur following propofol infusions in healthy individuals who do not subsequently develop adverse events as well [50] . Nonetheless, the observed lipemia is possibly related to an impending failure of hepatic lipid regulation (owing to poor oxygenation and lack of glucose supply), and in some reported cases it seemed to be the first indication of evolving PRIS.
ECG may show coved-type ST-segment elevation in the right precordial leads, similar to that observed in patients with the inherited Brugada syndrome (Fig. 1) . Vernooy et al. [40] suggested that such ECG changes can be an early warning sign of impending cardiac electrical instability. These authors systematically reviewed the ECGs of seven previously published cases of the PRIS and a further index case, and found that in seven out of eight patients the typical ECG pattern of down sloping ST-segment elevation in the right precordial leads (V1-V3) was present several hours prior to the development of the deleterious ventricular arrhythmias, which subsequently led to death.
Late features of the PRIS include signs of muscle cell necrosis and impaired cardiac contractility. Rhabdomyolysis will be signaled by a rise in creatine kinase concentrations in plasma and by myoglobinuria. Echocardiography will typically show globally impaired ventricular function but may detect structural abnormalities. Owing to rhabdomyolysis and forward failure, acute renal failure and hyperkalemia may eventually ensue. Additionally, abdominal echography may reveal fatty degeneration of the liver following prolonged hyperlipemia.
Both supraventricular and ventricular tachyarrhythmias without other identifiable causes, as well as cases of ventricular asystole with apparent total heart block, have been described in the final stages of the syndrome.
Risk factors
Several risk factors for the PRIS include large cumulative dose of propofol, young age, acute neurological injury, low carbohydrate intake, high fat intake, catecholamine infusion, corticosteroid infusion, critical illness, and inborn errors of mitochondrial fatty acid oxidation, as identified from the many published case reports. Typically, patients were exposed to relatively high infusion rates for considerable periods of time, rendering the total cumulative propofol dose as the most important risk factor. However, an important exception was reported by Machata et al. [36] , who described a case of the PRIS in a patient with TBI who received propofol at a rate of 'only' 3 mg/kg per hour for 72 h (although presumably propofol was given at a much higher dose during this patient's initial surgery). In a retrospective cohort study of 67 patients with TBI published in 2001, however, our group found that the syndrome did not occur in patients receiving mean propofol doses of less than 5 mg/kg per hour, whereas the incidence was 17 and 31% in patients receiving 5-6 and more than 6 mg/kg per hour, respectively [25] .
Children and young adults seem to be overrepresented among the reported cases of the PRIS (Table 2) , although it is difficult to establish this relation with certainty because of the skewed age distribution in patients with TBI. Nonetheless, children are possibly prone to the PRIS as a result of their lower glycogen stores and consequently higher dependency on fat metabolism [51] . Moreover, patients with acute neurological injury or disease are probably at risk to begin with, because of the increased central nervous system activation with production of catecholamines and glucocorticoids, which by itself can produce stress cardiomyopathy via myofibrillar degeneration and proteolysis [28, 52, 53] . Low carbohydrate intake, high lipid intake or inadequate clearance of fat, exogenous catecholamine and corticosteroid infusion and possibly inherited mitochondrial defects are among the other risk factors [28] .
Cause
On the basis of the reports of PRIS cases in head-injured patients, long-term high-dose propofol exposure appears to be a necessary cause for development of the syndrome, although it does not, in itself, seem to be a sufficient cause. Rather, in the majority of affected patients other Update on PRIS in patients with TBI Otterspoor et al. 545 In ml/h. risk factors were (also) present to contribute to the clinical deterioration that was observed [28, 54] . Furthermore, the PRIS is still a rather poorly defined disease entity, resembling frank multiorgan failure in its final stages. As a result, some authors in the past have expressed dissenting views, postulating that the cause of the syndrome in fact may not be related to propofol infusion at all, but rather to underlying disease processes in these critically ill patients [28, 54] . Alternatively, the recent report of a case that strongly resembled the PRIS following the infusion of thiopental to suppress cerebral metabolism has raised the question of whether the cause could actually consist of a fatal common pathway following the prolonged administration of any high-dose anesthetic, not specifically propofol [55 ] . A commonly used argument has been that, if a causal relation does exist, more evidence should be available given the large number of propofol applications worldwide [56] .
When judging an association for possible causality it is prudent to apply the criteria of Hill [57] . Table 3  ([58,59 ,60]) shows the nine classic criteria for causality [60] applied to the case of the PRIS. From Table 3 , it becomes evident that a causal relation is likely. Further evidence that supports causality has recently been contributed by Ypsilantis et al. [59 ] . In a well designed animal experiment, these authors observed signs and symptoms consistent with the PRIS in rabbits that were exposed to propofol 20-66 mg/kg per hour for up to 38 h. The study's two control groups consisted of rabbits exposed to equipotent doses of sevoflurane, or sevoflurane and Intralipid 10% (Kabivitrum Inc., California and Stockholm) (to mimic propofol's lipid vehicle). In these control groups, no signs of the PRIS were observed.
Pathophysiology
The proposed pathophysiology of the PRIS is multifactorial and likely involves a number of parallel acting mechanisms. For clarity, we will discuss these separately, although they act concurrently in affected patients.
Effects on the mitochondrion
An imbalance between energy demand and utilization appears to be a key pathogenetic mechanism in the PRIS. Ultimately, this imbalance can result in cardiac and peripheral muscle necrosis [28, 29] . In isolated rat liver mitochondria and guinea pig heart models, propofol uncouples oxidative phosphorylation and inhibits electron flow along the electron transport chain, decreasing the ability of mitochondria to produce energy [61, 62] . In critical conditions, free fatty acids (FFAs) derived from catecholamine-mediated lipolysis of adipose tissues are the most important fuel for myocardial and skeletal muscle cells. Intra-mitochondrial beta-spiral oxidation is the key process generating electrons, which are transferred to the respiratory chain. Any significant obstacle to FFA utilization caused by propofol will therefore result in some grade of cardiac and peripheral muscle myocytolysis [28] . Therefore, propofol should probably not be used in patients with an inborn error of mitochondrial fatty acid metabolism such as a very long chain acylcoenzyme A dehydrogenase deficiency [63, 64] . Interference of propofol with already impaired fatty acid oxidation in these patients will almost certainly cause severe metabolic acidosis.
Several authors have reported findings in PRIS cases that show resemblance to mitochondrial cytopathies and an acquired carnitine deficiency [16] . Muscle biopsy in a child with the PRIS described by Mehta et al. [13] revealed abnormalities consistent with an acquired respiratory chain enzyme deficiency. Cray et al. [10] demonstrated a reduction in mitochondrial cytochrome C oxidase activity in muscle cells consistent with respiratory chain disruption. Finally, Wolf et al. [16] showed that markers of fatty acid oxidation such as malonylcarnitine and C5-acylcarnitine were increased in a 2-year-old boy, who developed PRIS, findings that are also consistent with mitochondrial blockage. The child made a complete recovery following discontinuation of propofol and start of hemofiltration, and at follow-up all markers of fatty acid oxidation had returned to normal.
Effects on lipid metabolism
The carnitine molecule transports long-chain acyl groups from fatty acids into the mitochondrial matrix, so that they can be broken down through beta-oxidation to acetate, releasing energy via the citric acid cycle. Inhibition of beta-oxidation by propofol, as described above, would therefore be expected to result in an accumulation of FFA and acyl-carnitine complexes. Indeed, increased concentrations of plasmatic acyl-carnitine and its intermediates were measured in the blood of children sedated with propofol [10, 15] . High plasma concentrations of these unutilized FFAs have been shown to possess pro-arrhythmogenic properties [65] .
Ypsilantis et al. [59 ] used high-dose sedation in rabbits for periods up to 48 h and found that serum triglyceride concentrations were substantially increased in animals receiving propofol, whereas they were only moderately increased in animals receiving sevoflurane and Intralipid, despite similarly elevated cholesterol levels in both groups. This suggests a primary role for the propofol compound itself, rather than for the Intralipid carrier, in causing the lipemia commonly observed in PRIS cases. Possibly, this marked increase in triglyceride concentrations is directly caused by impaired beta-oxidation of FFAs induced by propofol, or, alternatively, by altered mobilization of FFAs from triglycerides. Indeed, it has been hypothesized that the increased sympathetic nervous system outflow and elevated cortisol and growth hormone concentrations commonly observed in critically ill patients may promote lipolysis and fat oxidation, resulting in a further increase in FFA concentrations [6] . Liver dysfunction due to circulatory failure or to direct hepatotoxic effects of propofol may adversely affect lipid kinetics as well. In the end, lipemia by itself can impair mitochondrial oxygen uptake, thus contributing to the accelerated development and refractory nature of the PRIS.
In patients with critical illness, carbohydrate reserves are commonly low or even exhausted. In the absence of carbohydrates, phosphorylated citrate levels fall and lipid metabolism slows. If lipid formulations such as propofol are infused and regulation is impaired, accumulation of triglycerides will begin shortly, reaching lipemic levels after approximately 2-5 days, depending on the administration rate [54] . Carbohydrate reserves are depleted more rapidly in children than in adults and this may explain the higher prevalence of the PRIS in children.
Propofol antagonizes beta-adrenoreceptor binding in animal models, explaining why higher doses of catecholamines may be needed in patients on propofol, compared with patients receiving equipotent doses of an alternative anesthetic [66] . In turn, the administration of catecholamines has been shown to decrease propofol plasma levels in sheep [67] . The latter effect is most likely explained by an increased propofol clearance due to a rise in cardiac output and portal flow. Similarly, the hyperdynamic state seen in the systemic inflammatory response syndrome can increase the clearance of propofol, and thus dose requirements [68] .
Simultaneously at work, these mechanisms of interaction have the potential to direct the intensive care physician towards a vicious circle of both progressively increasing the propofol infusion rate (resulting in hypotension) and increasing the catecholamine infusion rate (resulting in a decreased level of sedation).
The use of high doses of a catecholamine drug is associated with electrocardiographic signs of ischemia and histopathological findings such as myofibrillar degeneration or myocytolysis. This type of cardiac damage has also been observed after severe sympathetic stress such as following trauma, burns, major surgery, sepsis, asthma and various other conditions [69] . Clinically, this condition is known as tako tsubo (or 'stress') cardiomyopathy [70] . In patients with neurological disease such as major head trauma and acute subarachnoid hemorrhage, it is thought to result from the release of large quantities of norepinephrine into the myocardium by the sympathetic nerve terminals [71] .
Several critically ill patients who presented with the PRIS received high-dose steroids during their treatment. Steroids can promote proteolysis of the cardiac contractile myofilaments [52, 53] and may thus trigger acute muscle damage.
Genetic predisposition
The relatively rare occurrence of the PRIS considering the widespread use of propofol may be explained by the existence of a genetic susceptibility as a necessary cause such as a latent hereditary impairment of mitochondrial fatty acid oxidation. Indeed, patients with a deficiency of medium-chain acyl-coenzyme A dehydrogenase (MCADD) can present with acute metabolic decompensation during catabolic episodes that resembles those seen in the PRIS [72, 73] . Specific studies are needed to identify a genetic risk profile for the development of the PRIS.
Effects on heart rhythm
By reducing sympathetic tone more than parasympathetic tone, propofol can cause bradycardia, particularly in children. High-dose propofol may induce an imbalance in action potential ion currents leading to the Brugada ECG changes as described above. This causes electrical instability, which may lead to the development of malignant arrhythmias [40] . Propofol may also cause arrhythmia via indirect pathways, for example by increasing the FFA concentration in plasma, which carry antiarrhythmic properties [65] . Furthermore, severe illness itself can induce arrhythmias through myofibrillar degeneration as described above. Because this myofibrillar degeneration is predominantly subendocardial and consists of focal areas surrounded by an acute inflammatory reaction, it explains the early involvement of the cardiac conducting system and the risk of arrhythmias associated with the PRIS. Obviously, catecholamine infusions, acidosis and hyperkalemia will also contribute to the induction of arrhythmias.
Clinical management
Clinicians in the ICU should be extremely suspicious about the development of the PRIS when lactic acidosis develops and the need for inotropic support increases in a patient receiving propofol, in the absence of a well understood cause. Propofol should be discontinued immediately in such cases. In patients on propofol sedation, especially when a trigger such as TBI or other critical illness is present, it is advisable to monitor early warning signs such as lactate, creatine kinase and myoglobin levels, as well as to do ECG monitoring at least on a daily basis in order to detect ST-segment elevation in the right precordial leads.
Management of full-blown PRIS typically requires extensive cardiorespiratory support. Cardiac pacing has been used in some cases of life-threatening bradyarrhythmia [6, 10, 12, 16] .
Both hemodialysis and hemoperfusion to eliminate propofol and its metabolites have been used successfully, but the benefit of such treatment remains unproven [9, 16, 35] . Two reports have recorded the successful use of an extracorporeal membrane oxygenator for combined respiratory and circulatory support [11, 21] .
On the basis of the proposed pathophysiology of the syndrome, in particular the observed derangements in fatty acid metabolism, an adequate carbohydrate intake (6-8 mg/kg per minute) has been recommended to provide ample substrate to the failing mitochondria and suppress lipid oxidation [16, 54, 74] . Likewise, carnitine supplementation might be of some benefit at least on a theoretical basis [75] .
Conclusion
Over the last two decades, propofol has become an important agent for critical care sedation because of its distinct advantages in special situations such as severe head trauma. However, it is now clear that the potentially fatal occurrence of the PRIS limits its use, both in terms of maximum infusion rate and duration. Patients with TBI admitted to a neurocritical care unit are especially at risk for developing the PRIS because their condition can be accompanied by an excessive stress response with severe cardiovascular effects.
Until we know for certain whether the PRIS selectively affects only patients with a particular genetic profile, we recommend restricting the infusion of propofol to a maximum rate of 4 mg/kg per hour in patients with severe head injury and others who are at high risk (see 'Risk factors') and in need of prolonged sedation. In patients without risk factors, infusion of propofol at rates up to 5 mg/kg per hour may be acceptable for sedation in the ICU. If a clinically acceptable level of sedation cannot be obtained within these dosing restrictions, alternative drugs such as opioids, benzodiazepines or alpha-2 receptor agonists (dexmedetomidine and clonidine) should be used additionally. For anesthesia or short-term sedation, higher doses of propofol are generally required and can be used safely (maximum 15 mg/kg per hour for children and 12 mg/kg per hour for adults).
